# Diabetic Nephropathy Medication Optimization

11

# Diabetic Nephropathy Medication Optimization

✨ Enhanced Interactive Case with CONFIDENCE Trial Integration

⏱️ 75-90 min 🎯 Advanced Level 🔗 Multi-Module Integration ✨ Enhanced Interactive

##  Breaking: NEJM CONFIDENCE Trial Results (August 2025)

Revolutionary new evidence for combination therapy in diabetic nephropathy

#### 🎯 Primary Endpoint

**approximately 29% greater** UACR reduction vs. finerenone alone, **approximately 32% greater** vs. empagliflozin alone (between-arm comparator deltas at 180 days)

Within-arm reduction from baseline approximately 52% in combination arm

#### 💊 Finerenone + Empagliflozin

**29% greater** reduction vs. finerenone alone

**32% greater** reduction vs. empagliflozin alone

#### ⚡ Safety Profile

**No unexpected** adverse events

Hyperkalemia leading to discontinuation was uncommon

#### ⏰ Rapid Benefits

**Benefits within 180 days**

Peak effect achieved by 6 months

#### 📚 Study Reference

"Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes"

Agarwal R, Green JB, Heerspink HJL, et al. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. N Engl J Med. 2025;393(6):533-543. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40470996/)

##  Integrated Learning Modules

This enhanced case integrates content from multiple lecture modules for comprehensive diabetic nephropathy management

#### 🚨 Primary Module: CKD & Prevention

Diabetic nephropathy progression, SGLT2 inhibitors, albuminuria reduction strategies, combination therapy

#### ❤️ Supporting Module: Cardiorenal Disease

Integrated heart-kidney management, four-pillar GDMT, CONFIDENCE trial implications

#### 💓 Supporting Module: Hypertension Management

ARB optimization, dual RAAS blockade, BP targets in CKD

#### ⚡ Supporting Module: Electrolyte Disorders

Hyperkalemia management with potassium binders, SGLT2i effects on electrolytes

#### Quick Access to Related Content:

[🫘 CKD Module](https://urinenephrology.org/2025_UDPA_Lectures_Live/ckd/index.html) [❤️ Cardiorenal Disease](https://urinenephrology.org/2025_UDPA_Lectures_Live/cardiorenal-disease/index.html) [💓 Hypertension Module](https://urinenephrology.org/2025_UDPA_Lectures_Live/hypertension/index.html) [⚡ Electrolytes Module](https://urinenephrology.org/2025_UDPA_Lectures_Live/electrolytes/index.html)

##  Pre-Case Assessment: Test Your Baseline Knowledge

Answer these questions before reviewing the case to assess your starting knowledge

1

#### Based on the CONFIDENCE trial (Agarwal R et al., NEJM 2025, PMID 40470996), how much GREATER is the albuminuria reduction with combination finerenone + empagliflozin compared to either monotherapy at 180 days?

A\) Approximately 5-10% greater than either drug alone (modest additive effect) B) Combination is approximately 29% greater than finerenone alone and approximately 32% greater than empagliflozin alone (between-arm comparator deltas; within-arm reduction from baseline approximately 52%) C) Approximately 70-80% greater than either drug alone D) No significant additive benefit from combination **Correct Answer: B**\
**Learning Point:** CONFIDENCE (Agarwal NEJM 2025, PMID 40470996) had two endpoints worth distinguishing: (1) **within-arm** UACR reduction from baseline at 180 days was approximately 52% in the combination arm; (2) the **between-arm** primary endpoint — combination vs each monotherapy — showed combination was approximately **29% greater than finerenone alone** and approximately **32% greater than empagliflozin alone**. The 29%/32% comparator deltas are what justify combination over monotherapy. \
**📚 Reference:** [CKD Prevention Module](https://urinenephrology.org/2025_UDPA_Lectures_Live/ckd/index.html) 2

#### Which of the following best describes the primary mechanism by which SGLT2 inhibitors provide renal protection?

A\) Direct anti-inflammatory effects on glomerular cells B) Restoration of tubuloglomerular feedback and reduction in hyperfiltration C) Inhibition of the renin-angiotensin-aldosterone system D) Direct vasodilation of efferent arterioles **Correct Answer: B**\
**Learning Point:** SGLT2 inhibitors block glucose reabsorption in the proximal tubule, increasing glucose delivery to the macula densa, which activates tubuloglomerular feedback and reduces glomerular hyperfiltration.\
**📚 Reference:** [CKD Prevention Module](https://urinenephrology.org/2025_UDPA_Lectures_Live/ckd/index.html) 3

#### Which potassium binder is preferred for long-term hyperkalemia management in CKD patients?

A\) Sodium polystyrene sulfonate (SPS/Kayexalate) B) Patiromer (Veltassa) - safest long-term option C) Calcium polystyrene sulfonate D) Loop diuretics for potassium wasting **Correct Answer: B**\
**Learning Point:** Patiromer (Veltassa) is the safest long-term potassium binder. SPS causes colonic necrosis risk. Lokelma (sodium zirconium cyclosilicate) is excellent for acute management.\
**📚 Reference:** [Hyperkalemia Management](https://urinenephrology.org/2025_UDPA_Lectures_Live/electrolytes/potassium/hyperkalemia.html)

##  Case Presentation

**Patient:** 58-year-old Caucasian male

**Chief Complaint:** "My doctor says my kidney function is getting worse and wants me to see you"

**History:** Established patient with 12-year history of type 2 diabetes and 8-year history of hypertension. Recent routine labs show gradual decline in kidney function over the past 2 years. Currently experiences mild lower extremity edema and nocturia x2. Reports good glycemic control but acknowledges dietary sodium intake has been suboptimal.

**Past Medical History:** Type 2 diabetes (HbA1c 7.2%), hypertension, dyslipidemia, obesity (BMI 32), mild retinopathy

**Current Medications:**\
• Chlorthalidone 25mg daily\
• Atenolol 50mg daily\
• Losartan (Cozaar) 100mg daily\
• Metformin 1000mg BID\
• Atorvastatin 40mg daily

**Social History:** Non-smoker, rare alcohol use, works as construction supervisor, family history of diabetes and kidney disease

### 🤔 Initial Clinical Reasoning Questions

4

#### Given this patient's current medication regimen, which combination of side effects would you most expect to find?

A\) Hyperkalemia, hypermagnesemia, and hypouricemia B) Hypokalemia, hypomagnesemia, and hyperuricemia C) Hyperkalemia, hypomagnesemia, and hyperuricemia D) Hypokalemia, hypermagnesemia, and hypouricemia **Correct Answer: B**\
**Clinical Reasoning:** Chlorthalidone (thiazide-like diuretic) commonly causes the triad of hypokalemia, hypomagnesemia, and hyperuricemia through effects on distal tubule electrolyte handling and uric acid clearance.\
**📚 Learn More:** [Diuretic Selection Guide](https://urinenephrology.org/2025_UDPA_Lectures_Live/hypertension/diuretic-selection.html)

##  Laboratory Data & Analysis

### Current Laboratory Values

| Parameter | Current Value | 2 Years Ago | Normal Range | Clinical Significance |
|----|----|----|----|----|
| **Creatinine** | 1.6 mg/dL | 1.1 mg/dL | 0.7-1.3 mg/dL | CKD Stage 3a |
| **eGFR** | 48 mL/min/1.73m² | 78 mL/min/1.73m² | \>60 mL/min/1.73m² | Moderate decline |
| **Albumin/Creatinine Ratio** | 2000 mg/g | 450 mg/g | \<30 mg/g | Severe albuminuria (A3) |
| **Potassium** | 3.2 mEq/L | 4.1 mEq/L | 3.5-5.0 mEq/L | Hypokalemia |
| **Magnesium** | 1.4 mg/dL | 2.0 mg/dL | 1.7-2.2 mg/dL | Hypomagnesemia |
| **Uric Acid** | 9.8 mg/dL | 6.2 mg/dL | 3.5-7.2 mg/dL | Hyperuricemia |
| **HbA1c** | 7.2% | 7.8% | \<7.0% | Good glycemic control |
| **Blood Pressure** | 148/92 mmHg | 138/88 mmHg | \<130/80 mmHg | Above target for CKD |

### 📊 Laboratory Analysis Questions

5

#### What is the most likely explanation for this patient's current electrolyte abnormalities?

A\) Progressive CKD causing mineral bone disease B) Chlorthalidone-induced renal losses of potassium and magnesium C) Losartan-induced hyperkalemia being masked by diuretic effects D) Dietary restrictions causing electrolyte depletion **Correct Answer: B**\
**Learning Point:** Thiazide and thiazide-like diuretics cause characteristic losses of potassium and magnesium through enhanced distal tubule excretion, while also reducing uric acid clearance.\
**📚 Reference:** [Electrolyte Disorders Module](https://urinenephrology.org/2025_UDPA_Lectures_Live/electrolytes/index.html) 6

#### Based on the albuminuria level (2000 mg/g), what is the most appropriate classification and treatment approach?

A\) A2 (moderately increased albuminuria) - single-agent optimization sufficient B) A3 (severely increased albuminuria) - candidate for combination therapy per CONFIDENCE trial C) A1 (normal to mildly increased) - continue current therapy D) Nephrotic range proteinuria requiring immediate biopsy **Correct Answer: B**\
**Learning Point:** Albuminuria \>300 mg/g (A3 category) indicates severely increased albuminuria. CONFIDENCE (Agarwal NEJM 2025, PMID 40470996) studied this population and showed combination finerenone + empagliflozin produced approximately 29% greater UACR reduction than finerenone alone and approximately 32% greater than empagliflozin alone (between-arm comparator deltas at 180 days).\
**📚 Reference:** [CKD Staging and Combination Therapy](https://urinenephrology.org/2025_UDPA_Lectures_Live/ckd/index.html)

##  CONFIDENCE Trial-Informed Treatment Plan

### 🎯 Evidence-Based Medication Changes

#### 1️⃣ Discontinue Chlorthalidone

- Stop thiazide-induced K+ and Mg+ losses
- Reduce hyperuricemia burden
- Allow for optimization of other agents

#### 2️⃣ Switch to Olmesartan 40mg daily

- Active drug, not requiring conversion
- Superior renal protection evidence
- Start 20mg, target 40mg daily

#### 3️⃣ Add Empagliflozin 10mg daily

- CONFIDENCE trial medication
- Renal protection + CV benefits
- Will improve Mg levels

#### 4️⃣ Assess finerenone eligibility and starting dose

- CONFIDENCE trial partner medication
- Explain the trial-average UACR benefit; do not promise an individual reduction
- Kidney/CV outcome evidence in T2D with CKD; potassium monitoring remains essential

### 💊 CONFIDENCE Trial Application Questions

7

#### Based on the CONFIDENCE trial, what are the expected benefits of combination finerenone + empagliflozin in this patient?

A\) Modest 15-20% albuminuria reduction with minimal electrolyte effects B) 50-60% albuminuria reduction, normalized electrolytes, improved BP control C) Complete normalization of kidney function within 6 months D) Primarily glycemic benefits with minimal renal effects **Correct Answer: B**\
**CONFIDENCE Trial Evidence (Agarwal NEJM 2025, PMID 40470996):** Combination finerenone + empagliflozin produced approximately 29% greater UACR reduction than finerenone alone and approximately 32% greater than empagliflozin alone (between-arm comparator deltas at 180 days; within-arm reduction from baseline was approximately 52%). SGLT2 inhibitors improve magnesium homeostasis and provide modest BP reduction (3-5 mmHg), while finerenone adds additional albuminuria reduction.\
**📚 Reference:** [CONFIDENCE Trial Results](https://urinenephrology.org/2025_UDPA_Lectures_Live/ckd/index.html) 8

#### What supports selecting finerenone for this patient with T2D and albuminuric CKD?

A\) Finerenone has better anti-hypertensive effects B) Dedicated kidney/CV outcome evidence in eligible T2D with CKD; potassium monitoring is still required C) Finerenone is more cost-effective than spironolactone D) Better tolerability with fewer GI side effects **Correct Answer: B**\
**Clinical Advantage:** FIDELIO-DKD and FIGARO-DKD established kidney/CV outcome benefits versus placebo in eligible T2D with CKD. CONFIDENCE demonstrated greater UACR reduction with combination therapy at 180 days. These trials do not establish lower hyperkalemia risk than spironolactone in a comparable head-to-head outcome trial; choose by indication and monitor potassium.\
**📚 Reference:** [Non-steroidal MRAs in Diabetic Kidney Disease](https://urinenephrology.org/2025_UDPA_Lectures_Live/ckd/index.html)

##  Interactive Treatment Timeline & Expected Outcomes

#### Week 0-2: Medication Transition Period

**Actions:** Discontinue chlorthalidone, switch losartan to olmesartan 20mg daily

**Monitoring:** Daily home BP monitoring, BMP in 1 week

**Expected:** Initial BP may increase 5-10 mmHg as thiazide effect wanes

**Safety:** Watch for hyperkalemia as thiazide washout occurs

#### Week 2-4: SGLT2 Inhibitor Introduction

**Actions:** Start empagliflozin 10mg daily, increase olmesartan to 40mg daily

**Monitoring:** eGFR, urinalysis, BP trends, weight changes

**Expected:** Initial creatinine rise 0.1-0.2 mg/dL (temporary), weight loss 2-3 lbs

**Counseling:** Discuss euglycemic DKA prevention, genital hygiene

#### Week 4-8: Finerenone Addition (CONFIDENCE Protocol)

**Actions:** If eligible, initiate finerenone 10 mg daily at eGFR 25 to below 60, or 20 mg at eGFR 60 or above, following the CKD/T2D label. Do not initiate if K+ exceeds 5.0 mEq/L; 4.8-5.0 requires additional monitoring.

**Monitoring:** Weekly K+ for 4 weeks, monthly BMP thereafter

**Expected:** Begin to see significant albuminuria improvement per CONFIDENCE trial

**Target:** BP \<130/80 mmHg, stable or improved eGFR

#### Month 3: CONFIDENCE Trial Efficacy Assessment

**Laboratory Goals:** 50-60% reduction in albuminuria (target \<800 mg/g)

**BP Target:** Achieved \<130/80 mmHg

**Metabolic Effects:** Normalized K+ and Mg+, reduced uric acid

**Renal Function:** Creatinine plateau at 1.8 mg/dL (acceptable increase)

### ⏰ Treatment Timeline Questions

9

#### During week 2-4, the patient's creatinine rises from 1.6 to 1.8 mg/dL. What is the most appropriate action?

A\) Immediately discontinue empagliflozin due to AKI B) Reduce olmesartan dose to 20mg daily C) Continue current regimen as this represents expected hemodynamic changes D) Add a diuretic to improve volume status **Correct Answer: C**\
**Hemodynamic Insight:** An early modest creatinine rise can reflect the expected hemodynamic effect of SGLT2 therapy, but is not an individual predictor of benefit. Assess volume, symptoms, concurrent medicines, and the trajectory; progressive change or illness requires evaluation.\
**📚 Reference:** [SGLT2i Hemodynamic Effects](https://urinenephrology.org/2025_UDPA_Lectures_Live/ckd/index.html)

##  Learning Objectives Assessment

Evaluate your mastery of the key learning objectives from this case

#### 🎯 Learning Objective 1: CONFIDENCE Trial Application

**Objective:** Apply combination therapy evidence to optimize diabetic nephropathy outcomes

10

#### A 45-year-old patient with diabetic nephropathy (eGFR 35, albuminuria 1800 mg/g) is on lisinopril and metformin. Based on CONFIDENCE trial evidence, what is the optimal next step?

A\) Increase lisinopril dose and add spironolactone B) Add empagliflozin and finerenone for combination therapy C) Switch to olmesartan and add conventional diuretic D) Add only empagliflozin and monitor response **Correct Answer: B**\
**Competency Demonstration:** CONFIDENCE (Agarwal NEJM 2025, PMID 40470996) showed combination finerenone + empagliflozin achieved approximately 29% greater UACR reduction than finerenone alone and approximately 32% greater than empagliflozin alone (between-arm comparator deltas at 180 days; within-arm baseline reduction approximately 52%). This patient fits the trial population perfectly.\
**📚 Master This:** [CONFIDENCE Trial Implementation](https://urinenephrology.org/2025_UDPA_Lectures_Live/ckd/index.html)

#### 🎯 Learning Objective 2: SGLT2 Inhibitor Hemodynamic Effects

**Objective:** Understand and manage expected creatinine changes with SGLT2 inhibitors

11

#### Which change in kidney function after starting empagliflozin indicates appropriate hemodynamic response?

A\) \>30% decrease in eGFR within 4 weeks B) 10-20% decrease in eGFR that stabilizes within 4-8 weeks C) No change in eGFR D) Progressive decline in eGFR over 12 weeks **Correct Answer: B**\
**Hemodynamic Mastery:** An early reversible eGFR dip can reflect reduced intraglomerular pressure. Stabilization with preserved perfusion supports continued indicated treatment; the dip itself does not prove long-term benefit or exclude another cause of AKI.\
**📚 Master This:** [SGLT2i Renal Hemodynamics](https://urinenephrology.org/2025_UDPA_Lectures_Live/ckd/index.html)

#### 🎯 Learning Objective 3: Hyperkalemia Management in Combination Therapy

**Objective:** Safely manage hyperkalemia to maintain optimal therapy

12

#### What is the expected combined effect of olmesartan + empagliflozin + finerenone on albuminuria based on current evidence?

A\) 20-30% reduction B) 50-70% reduction with potential for sub-nephrotic range achievement C) 80-90% reduction to normal levels D) Variable response depending on baseline glucose control **Correct Answer: B**\
**Evidence Integration:** CONFIDENCE (Agarwal NEJM 2025, PMID 40470996) showed combination finerenone + empagliflozin produces approximately 29–32% greater UACR reduction than either agent alone (between-arm comparator delta at 180 days). Within-arm UACR reduction from baseline was approximately 52% in the combination arm. Triple therapy with optimal ARB + SGLT2i + MRA can achieve substantial albuminuria reduction, often moving patients from macro- to microalbuminuria range.\
**📚 Master This:** [Combination Therapy for Diabetic Nephropathy](https://urinenephrology.org/2025_UDPA_Lectures_Live/ckd/index.html)

##  Module-Specific Deep Dive: Nephroprotective Pharmacology

Advanced understanding of medication mechanisms and evidence in diabetic kidney disease

13

#### What is the mechanism by which SGLT2 inhibitors reduce albuminuria independent of glucose lowering?

A\) Direct podocyte stabilization through receptor binding B) Restoration of tubuloglomerular feedback by increasing sodium delivery to the macula densa, causing afferent arteriolar constriction and reduced intraglomerular pressure C) Inhibition of the renin-angiotensin system at the juxtaglomerular apparatus D) Reduction of renal blood flow through systemic vasoconstriction **Correct Answer: B**\
**Learning Point:** In diabetic nephropathy, proximal tubule glucose-sodium reabsorption is upregulated via SGLT2, reducing sodium delivery to the macula densa. This suppresses tubuloglomerular feedback, causing afferent arteriolar dilation and glomerular hyperfiltration. SGLT2 inhibitors restore normal sodium delivery to the macula densa, re-activating tubuloglomerular feedback, constricting the afferent arteriole, and reducing intraglomerular pressure. This explains the initial "hemodynamic dip" in eGFR (beneficial, similar to ACE/ARB) and the glucose-independent renoprotective effect seen in DAPA-CKD (non-diabetic CKD patients also benefited).\
**📚 Reference:** [SGLT2i Mechanism of Renoprotection](https://urinenephrology.org/2025_UDPA_Lectures_Live/ckd/index.html) 14

#### The CONFIDENCE trial compared finerenone + empagliflozin versus empagliflozin alone in patients with CKD and type 2 diabetes. What was the primary endpoint result?

A\) No additional benefit from adding finerenone to SGLT2 inhibitor therapy B) Combination therapy achieved approximately 32% greater UACR reduction compared to empagliflozin alone at 180 days (approximately 6 months) C) Finerenone alone was superior to the combination due to fewer side effects D) The trial was stopped early due to excess hyperkalemia in the combination arm **Correct Answer: B**\
**Learning Point:** CONFIDENCE (Agarwal R et al. *NEJM* 2025, PMID 40470996) demonstrated that combination finerenone + empagliflozin achieved approximately **32% greater UACR reduction than empagliflozin alone and approximately 29% greater than finerenone alone** at **180 days (approximately 6 months)**. This supports a multi-target approach in diabetic nephropathy: ARB (efferent arteriole) + SGLT2i (afferent arteriole) + MRA (anti-fibrotic/anti-inflammatory). The combination was well-tolerated with manageable hyperkalemia rates. \
**📚 Reference:** [CONFIDENCE Trial Results](https://urinenephrology.org/2025_UDPA_Lectures_Live/ckd/index.html)

##  Integration Challenge: Complex Clinical Scenarios

15

#### At 3-month follow-up, the patient has achieved target BP (125/78) and 60% albuminuria reduction (800 mg/g), but develops K+ 5.2 mEq/L. What is the best management approach?

A\) Discontinue finerenone immediately B) Reduce olmesartan dose to 20mg daily C) Continue finerenone at same dose and monitor K+ with consideration of Lokelma if hyperkalemia persists D) Add a thiazide diuretic for K+ management **Correct Answer: C**\
**Integration Mastery:** With excellent clinical response (60% albuminuria reduction), maintaining current therapy with K+ binder is preferred. Lokelma (sodium zirconium cyclosilicate) 10g daily can effectively manage mild hyperkalemia while preserving life-saving therapy.\
**📚 Master This:** [Modern Hyperkalemia Management](https://urinenephrology.org/2025_UDPA_Lectures_Live/electrolytes/potassium/hyperkalemia.html) 16

#### The patient asks about genetic testing for medication optimization. With multiple effective ARB options available, what would you recommend?

A\) Genetic testing is not necessary given the availability of multiple effective ARB options and our current success B) Order CYP2C9 testing immediately to optimize losartan therapy C) Genetic testing should be done for all diabetes patients D) Wait until therapy fails before considering genetic testing **Correct Answer: A**\
**Practical Application:** With excellent clinical response on current therapy and multiple effective ARB options available, genetic testing offers minimal additional benefit. Focus resources on optimizing proven effective therapy rather than searching for theoretical improvements.\
**📚 Master This:** [Practical Pharmacogenomics](https://urinenephrology.org/2025_UDPA_Lectures_Live/hypertension/pharmacogenomics.html)

##  Advanced Clinical Integration

Apply multi-system knowledge to complex diabetic nephropathy management decisions

17

#### After starting empagliflozin, the patient's eGFR drops from 48 to 42 mL/min/1.73m² at 2 weeks. What is the appropriate response?

A\) Discontinue empagliflozin immediately due to nephrotoxicity B) Continue empagliflozin -- this is an expected hemodynamic dip (less than 30% from baseline) that reflects reduced intraglomerular pressure and predicts long-term renal benefit C) Reduce empagliflozin dose and recheck in 1 month D) Add IV fluids to correct presumed volume depletion from SGLT2 inhibitor osmotic diuresis **Correct Answer: B**\
**Learning Point:** The initial eGFR dip with SGLT2 inhibitors (typically 3-5 mL/min, up to 30% in some patients) is a hemodynamic effect reflecting reduced intraglomerular pressure -- the same mechanism that provides long-term renoprotection. This mirrors the ACE/ARB experience: a modest stable dip alone is not usually a reason to stop. Investigate a large/progressive decline, symptomatic depletion, or intercurrent AKI; ketoacidosis risk, prolonged fasting, surgery, and critical illness are separate reasons for temporary withholding. The eGFR typically stabilizes within 4-6 weeks and then declines more slowly than without the drug.\
**📚 Reference:** [SGLT2i Hemodynamic Dip Management](https://urinenephrology.org/2025_UDPA_Lectures_Live/ckd/index.html) 18

#### Why is losartan a suboptimal ARB choice for this patient compared to olmesartan or telmisartan?

A\) Losartan has higher rates of angioedema than other ARBs B) Losartan requires CYP2C9 conversion to its active metabolite (EXP-3174), making it susceptible to genetic polymorphisms and drug interactions; olmesartan and telmisartan are active parent compounds C) Losartan has no evidence for renal protection in diabetic nephropathy D) Losartan causes more hyperkalemia than other ARBs due to mineralocorticoid receptor antagonism **Correct Answer: B**\
**Learning Point:** Losartan is a prodrug that requires CYP2C9 metabolism to form the active metabolite EXP-3174, which has 10-40x greater AT1 receptor affinity. Approximately 8% of Caucasians and up to 20% of some Asian populations are CYP2C9 poor metabolizers, resulting in reduced active metabolite formation and inadequate BP/renal protection. Olmesartan, telmisartan, and valsartan are active parent compounds that do not require hepatic activation. Additionally, losartan has the shortest half-life (6-9 hours) among ARBs and does not provide full 24-hour coverage, whereas olmesartan (13 hours) and telmisartan (24 hours) offer superior trough coverage.\
**📚 Reference:** [ARB Pharmacogenomics & Selection](https://urinenephrology.org/2025_UDPA_Lectures_Live/hypertension/pharmacogenomics.html) 19

#### What differentiates finerenone from spironolactone in the management of diabetic kidney disease?

A\) Finerenone is more potent at blood pressure reduction than spironolactone B) Spironolactone has better evidence for cardiovascular outcomes in DKD C) Finerenone is a nonsteroidal MRA with kidney/CV outcome evidence in eligible T2D with CKD; its indication and monitoring differ from spironolactone D) Both drugs have identical mechanisms but finerenone is simply a newer formulation **Correct Answer: C**\
**Learning Point:** Finerenone has demonstrated kidney/CV benefit versus placebo in eligible T2D with CKD. Spironolactone has different evidence and indications, including HFrEF and resistant hypertension. Cross-trial event percentages do not prove one agent is safer or more effective than the other. Check the indication, kidney function, potassium, interactions, and monitoring plan before selecting an MRA.\
**📚 Reference:** [MRA Selection in Diabetic Nephropathy](https://urinenephrology.org/2025_UDPA_Lectures_Live/ckd/index.html) 20

#### The patient's chlorthalidone was discontinued as part of medication optimization. Which metabolic benefits would you expect from this change?

A\) Improved glycemic control only B) Correction of hypokalemia only C) Resolution of hypokalemia, hypomagnesemia, and hyperuricemia -- all thiazide-induced metabolic complications that were worsening this patient's kidney disease progression D) No metabolic benefit -- chlorthalidone discontinuation only affects blood pressure **Correct Answer: C**\
**Learning Point:** Thiazide/thiazide-like diuretics cause a characteristic metabolic triad: hypokalemia, hypomagnesemia, and hyperuricemia. Each of these independently accelerates CKD progression: (1) Hypokalemia promotes tubulointerstitial fibrosis and impairs insulin secretion (worsening diabetes), (2) Hypomagnesemia increases cardiovascular risk and insulin resistance, (3) Hyperuricemia is associated with faster eGFR decline. Discontinuing chlorthalidone and replacing BP control with SGLT2 inhibitor + optimized ARB + finerenone provides superior renoprotection without these metabolic costs.\
**📚 Reference:** [Diuretic Metabolic Effects](https://urinenephrology.org/2025_UDPA_Lectures_Live/hypertension/diuretic-selection.html) 21

#### At what eGFR threshold should empagliflozin be initiated vs. continued in a patient with diabetic kidney disease, and what is the evidence basis?

A\) Can only be started above eGFR 45 and must be stopped below 30 B) No eGFR restriction -- can be started at any level of kidney function C) Can be initiated down to eGFR 20 mL/min and continued even below 20 as long as tolerated, based on EMPA-KIDNEY and updated KDIGO guidelines D) Must be started above eGFR 60 for any glycemic benefit **Correct Answer: C**\
**Learning Point:** EMPA-KIDNEY (2022) extended the evidence for SGLT2 inhibitor renoprotection to patients with eGFR as low as 20 mL/min. Updated KDIGO 2024 guidelines recommend initiation of SGLT2i for CKD patients with eGFR 20 or greater. Once initiated, the drug can be continued below eGFR 20 as the renoprotective benefit persists (reduced intraglomerular pressure, anti-inflammatory effects) even though glycemic efficacy diminishes. The glycosuric effect is minimal below eGFR 30, but the cardiorenal benefits remain. This represents a paradigm shift from the earlier glucose-centric prescribing approach.\
**📚 Reference:** [SGLT2i eGFR Thresholds & EMPA-KIDNEY](https://urinenephrology.org/2025_UDPA_Lectures_Live/ckd/index.html)

##  Three-Month Follow-up: CONFIDENCE Trial Success Replicated

### Follow-up Laboratory Results

| Parameter | Baseline | 3-Month Follow-up | CONFIDENCE Target | Achievement Status |
|----|----|----|----|----|
| **Albumin/Creatinine Ratio** | 2000 mg/g | 850 mg/g | \<1000 mg/g (57% reduction) | ✓ Achieved (57% reduction - matches CONFIDENCE trial) |
| **Blood Pressure** | 148/92 mmHg | 125/78 mmHg | \<130/80 mmHg | ✓ Achieved |
| **Creatinine** | 1.6 mg/dL | 1.8 mg/dL | Stable (expected rise) | ✓ Expected hemodynamic effect |
| **Potassium** | 3.2 mEq/L | 5.2 mEq/L | 3.5-5.0 mEq/L | ⚠️ Mild hyperkalemia - manageable with K+ binder |
| **Magnesium** | 1.4 mg/dL | 1.9 mg/dL | 1.7-2.2 mg/dL | ✓ Normalized |
| **Uric Acid** | 9.8 mg/dL | 6.8 mg/dL | \<7.0 mg/dL | ✓ Significant improvement |
| **HbA1c** | 7.2% | 6.8% | \<7.0% | ✓ Improved glycemic control |

#### 🎉 CONFIDENCE Trial Success Replicated

- **Albuminuria Reduction:** 57% decrease (2000 → 850 mg/g) - exceeds CONFIDENCE trial results
- **Blood Pressure Control:** Achieved optimal target (\<130/80)
- **Electrolyte Improvement:** Mg+ normalized, K+ manageable with binder if needed
- **Uric Acid Improvement:** 31% reduction with thiazide discontinuation
- **Acceptable Hemodynamic Response:** Temporary creatinine rise stabilized
- **Improved Glycemic Control:** Additional benefit from empagliflozin

##  Case Reflection & Multi-Module Integration

#### 🫘 CKD & Prevention Integration

- CONFIDENCE trial application in real-world practice
- Combination therapy superiority over monotherapy
- SGLT2i hemodynamic effects and renal protection

[Review Complete CKD Module](https://urinenephrology.org/2025_UDPA_Lectures_Live/ckd/index.html)

#### ❤️ Cardiorenal Disease Integration

- Four-pillar GDMT optimization strategies
- Modern combination therapy approaches
- Integrated heart-kidney protection

[Review Cardiorenal Module](https://urinenephrology.org/2025_UDPA_Lectures_Live/cardiorenal-disease/index.html)

#### ⚡ Electrolyte Disorders Integration

- Modern hyperkalemia management with K+ binders
- SGLT2i effects on magnesium homeostasis
- Practical potassium management strategies

[Review Electrolytes Module](https://urinenephrology.org/2025_UDPA_Lectures_Live/electrolytes/index.html)

#### 💓 Hypertension Management Integration

- ARB selection and optimization principles
- BP targets in diabetic CKD patients
- Evidence-based medication sequencing

[Review Hypertension Module](https://urinenephrology.org/2025_UDPA_Lectures_Live/hypertension/index.html)

### 🎯 Key Integration Concepts

This case demonstrates the transformative power of evidence-based combination therapy in diabetic nephropathy. The CONFIDENCE trial provides level 1 evidence that simultaneous initiation of finerenone and empagliflozin achieves superior albuminuria reduction compared to either agent alone. By understanding modern hyperkalemia management with potassium binders, we can safely maintain optimal therapy even when mild electrolyte abnormalities develop. The 57% albuminuria reduction achieved in this patient represents a paradigm shift in our ability to slow diabetic kidney disease progression.

## 📝 Case Summary & Clinical Pearls

This enhanced case demonstrates the real-world application of the CONFIDENCE trial in diabetic nephropathy management. The patient achieved remarkable clinical outcomes including 57% albuminuria reduction, optimal blood pressure control, and normalization of most electrolyte abnormalities through strategic evidence-based combination therapy.

### 🔑 Key Clinical Pearls from This Case:

- **CONFIDENCE Trial Application:** Combination finerenone + empagliflozin achieves 50-60% albuminuria reduction
- **SGLT2i Hemodynamics:** An early modest creatinine rise may be hemodynamic; interpret the trajectory and perfusion
- **Modern K+ Management:** Lokelma and Veltassa allow maintenance of optimal therapy despite mild hyperkalemia
- **Combination Synergy:** Evidence-based dual therapy superior to sequential monotherapy optimization
- **Practical Genetics:** With multiple effective options available, genetic testing offers minimal added value

#### 🎓 Ready for the Next Challenge?

[← Previous Case](https://urinenephrology.org/2025_UDPA_Lectures_Live/cases/case10_enhanced.html) [→ Next Case](https://urinenephrology.org/2025_UDPA_Lectures_Live/cases/case12_enhanced.html) [📋 All Cases](https://urinenephrology.org/2025_UDPA_Lectures_Live/cases/index.html)

## 📚 References

1.  **Agarwal R, Green JB, Heerspink HJL, et al.; CONFIDENCE Investigators.** Combination finerenone and empagliflozin in chronic kidney disease and type 2 diabetes. *N Engl J Med* 2025; published online ahead of print. PMID: 40470996. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40470996/) *— CONFIDENCE; combination finerenone + empagliflozin produced approximately 29% greater UACR reduction than finerenone alone and approximately 32% greater than empagliflozin alone at 180 days (between-arm comparator deltas); within-arm reduction from baseline approximately 52%. The trial behind this case's combination strategy.*
2.  **Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC; DAPA-CKD Trial Committees and Investigators.** Dapagliflozin in patients with chronic kidney disease. *N Engl J Med* 2020;383(15):1436–46. PMID: 32970396. [PubMed](https://pubmed.ncbi.nlm.nih.gov/32970396/) *— DAPA-CKD; SGLT2i in CKD ± T2DM; primary kidney composite HR 0.61 (95% CI 0.51–0.72); ARR 5.3% over 2.4 years, NNT 19. The foundational SGLT2i CKD trial.*
3.  **The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R.** Empagliflozin in patients with chronic kidney disease. *N Engl J Med* 2023;388(2):117–27. PMID: 36331190. [PubMed](https://pubmed.ncbi.nlm.nih.gov/36331190/) *— EMPA-KIDNEY; broad CKD population including non-diabetic; primary kidney/CV composite HR 0.72 (0.64–0.82); confirmed SGLT2i benefit independent of diabetes.*
4.  **Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators.** Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *N Engl J Med* 2019;380(24):2295–306. PMID: 30990260. [PubMed](https://pubmed.ncbi.nlm.nih.gov/30990260/) *— CREDENCE; canagliflozin in T2DM with macroalbuminuria; HR 0.70 for primary composite; the original SGLT2i renal-outcome trial.*
5.  **Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD Investigators.** Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. *N Engl J Med* 2020;383(23):2219–29. PMID: 33264825. [PubMed](https://pubmed.ncbi.nlm.nih.gov/33264825/) *— FIDELIO-DKD; finerenone in T2DM with CKD; primary kidney composite HR 0.82 (0.73–0.93); ARR 3.4%, NNT 29 over 2.6 years. Establishes finerenone for renal-outcome reduction in DKD.*
6.  **Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM; FIGARO-DKD Investigators.** Cardiovascular events with finerenone in kidney disease and type 2 diabetes. *N Engl J Med* 2021;385(24):2252–63. PMID: 34449181. [PubMed](https://pubmed.ncbi.nlm.nih.gov/34449181/) *— FIGARO-DKD; finerenone CV-outcome companion to FIDELIO; primary CV composite HR 0.87 (0.76–0.98); ARR 1.4%, NNT 71. Together with FIDELIO establishes finerenone as a Class I option in DKD per KDIGO 2024.*
7.  **Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, Baeres FMM, Idorn T, Bosch-Traberg H, Lausvig NL, Pratley R; FLOW Trial Committees and Investigators.** Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. *N Engl J Med* 2024;391(2):109–21. PMID: 38785209. [PubMed](https://pubmed.ncbi.nlm.nih.gov/38785209/) *— FLOW; semaglutide GLP-1 RA in T2DM with CKD; primary kidney composite HR 0.76 (0.66–0.88); ARR 4.7%, NNT 21 over 3.4 years. Adds GLP-1 RA to the renal-protective regimen.*
8.  **Rossing P, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, Khunti K, Liew A, Michos ED, Navaneethan SD, Olowu WA, Sadusky T, Tandon N, Tuttle KR, Wanner C, Wilkens KG, Zoungas S, de Boer IH; KDIGO Diabetes Work Group.** KDIGO 2022 Clinical Practice Guideline for diabetes management in chronic kidney disease. *Kidney Int* 2022;102(5S):S1–S127. PMID: 36272764. [PubMed](https://pubmed.ncbi.nlm.nih.gov/36272764/) *— current KDIGO DM-CKD guideline; pillared therapy (RAS inhibitor + SGLT2i + ns-MRA + GLP-1 RA when indicated); the management framework operationalized in this case.*
9.  **ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA; American Diabetes Association.** Standards of Care in Diabetes—2024. *Diabetes Care* 2024;47(Suppl 1):S219–30. PMID: 38078574. [PubMed](https://pubmed.ncbi.nlm.nih.gov/38078574/) *— ADA 2024 Standards (CKD chapter); aligned with KDIGO; SGLT2i and GLP-1 RA Class I in T2DM with CKD; complementary management framework.*
10. **Heidenreich PA, Bozkurt B, Aguilar D, et al.** 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. *Circulation* 2022;145(18):e895–e1032. PMID: 35363499. [PubMed](https://pubmed.ncbi.nlm.nih.gov/35363499/) *— current HF guideline; SGLT2i Class I in HFrEF; relevant given the cardiorenal overlap in this DKD population.*

📚 For Educational Purposes Only - Enhanced Interactive Case-Based Learning Module

© 2025 Andrew Bland MD - All Rights Reserved


---

[Website version](https://urinenephrology.org/2025_UDPA_Lectures_Live/cases/case11_enhanced.html) · Markdown synchronized October 3, 2026.